ArticleJHEP reports : innovation in hepatology2026
Quantifying risk modifiers of hereditary hemochromatosis using genomic and electronic health record data.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsHereditary hemochromatosis is an autosomal recessive disorder of excessive iron accumulation. Early diagnosis enables treatment before organ damage. The C282Y variant in the HFE gene is the main cause, but its penetrance of only 20% limits its utility for population-wide screening. We aimed to identify and quantify novel genetic and non-genetic modifiers of C282Y-related disease from electronic healthcare records, and thereby partly explain its incomplete penetrance.
methodsWe carried out a cohort study on data from 420,543 individuals in the FinnGen project, for whom genotype information and healthcare records were available. We performed both standard and interaction genome-wide association study analyses for hemochromatosis and fitted statistical models including age, sex, 21 million genetic variants, preceding diagnoses, and blood donation history as predictors. Results were validated using data from the UK Biobank.
resultsWe identified three novel fine-mapped variants within 4 Mb of the HFE gene. Of these, variant rs181949568 in the CASC15 gene remained significant in the multivariable model (odds ratio 7.25, 95% CI 3.63-28.87, p = 1.96 × 10
conclusionsWe demonstrated that use of large-scale electronic health record data allows for precise quantification of individual-level risk, which we present as risk tables to support clinical practice. Furthermore, our findings suggest that hemochromatosis may be under-recognized in Finland. IMPACT AND IMPLICATIONS: Because the factors influencing the penetrance of the C282Y variant in hemochromatosis remain incompletely understood, a study leveraging newly available large-scale healthcare and genetic data is warranted. We present the findings of our study as an individual-level risk table designed for practicing clinicians, summarizing the combined effects of key variables most frequently observed in the dataset. Our results suggest that asymptomatic individuals who are homozygous for C282Y could significantly reduce their risk of developing hemochromatosis by donating blood just twice a year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.